SCHEMBL4635907

SCHEMBL4635907

CCCOC(=O)c1cc(O)ccc1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC28A3 Q9HAS3 5/20 0.54
TYR P14679 2/20 0.51
SLC5A1 P13866 3/20 0.51
SLC5A2 P31639 2/20 0.51
POLB P06746 2/20 0.50
KDM4E B2RXH2 2/20 0.50
MAPT P10636 2/20 0.50
GAA P10253 1/20 0.50
G6PD P11413 1/20 0.50
MAPK1 P28482 1/20 0.50
ADRA1A P35348 1/20 0.50
PTGS2 P35354 1/20 0.50
AKR1B1 P15121 1/20 0.50
DPP4 P27487 1/20 0.50
HPGD P15428 2/20 0.49
HSD17B10 Q99714 2/20 0.49
CYP3A4 P08684 1/20 0.49
THRB P10828 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7780249 0.94 TYR (0.52) SLC28A3TYRSLC5A1SLC5A2POLB
SCHEMBL7773584 0.93 PTPN1 (0.50) SLC28A3TYRSLC5A1SLC5A2AKR1B1
SCHEMBL7773575 0.92 PTPN1 (0.52) SLC28A3TYRSLC5A1SLC5A2AKR1B1
SCHEMBL7781029 0.92 PTPN1 (0.52) SLC28A3TYRSLC5A1SLC5A2AKR1B1
SCHEMBL7781033 0.92 PTPN1 (0.52) SLC28A3TYRSLC5A1SLC5A2AKR1B1
SCHEMBL7778438 0.92 PTPN1 (0.52) SLC28A3TYRSLC5A1SLC5A2AKR1B1
SCHEMBL7778012 0.92 PTPN1 (0.52) SLC28A3TYRSLC5A1SLC5A2AKR1B1
SCHEMBL7780420 0.92 PTPN1 (0.52) SLC28A3TYRSLC5A1SLC5A2AKR1B1
SCHEMBL7778445 0.92 PTPN1 (0.52) SLC28A3TYRSLC5A1SLC5A2AKR1B1
SCHEMBL7780191 0.92 PTPN1 (0.52) SLC28A3TYRSLC5A1SLC5A2AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1932514-B1 PHARMACEUTICAL PREPARATION FOR EXTERNAL APPLICATION TO SKIN COMPRISING PHOSPHORYLATED SUGAR EZAKI GLICO CO (JP) 2018-11-14 EP disclosed
US-20140023602-A1 EXTERNAL PREPARATION FOR SKIN CONTAINING A PHOSPHORYLATED SACCHARIDE EZAKI GLICO CO., LTD. (JP) 2014-01-23 US disclosed
US-20080274068-A1 External Preparation for Skin Containing a Phosphorlated Saccharide EZAKI GLICO CO., LTD. (JP) 2008-11-06 US disclosed
EP-1932514-A1 PHARMACEUTICAL PREPARATION FOR EXTERNAL APPLICATION TO SKIN COMPRISING PHOSPHORYLATED SUGAR Ezaki Glico Co., Ltd. (JP) 2008-06-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140023602-A1 EXTERNAL PREPARATION FOR SKIN CONTAINING A PHOSPHORYLATED SACCHARIDE SI, CUTA, CD44 SLC28A3 1164/4885TYR 149/4885SLC5A1 723/4885
US-20080274068-A1 External Preparation for Skin Containing a Phosphorlated Saccharide CUTA, SI, CD44 SLC28A3 977/4885TYR 113/4885SLC5A1 589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.